Chemoenzymatic Synthesis of Heparin Oligosaccharides with both Anti-factor Xa and Anti-factor IIa Activities

被引:38
|
作者
Xu, Yongmei [1 ]
Pempe, Elizabeth H. [1 ]
Liu, Jian [1 ]
机构
[1] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
INDUCED THROMBOCYTOPENIA; ANTITHROMBIN-III; TERNARY COMPLEX; SULFATE; ANTICOAGULANT; BINDING; BIOSYNTHESIS; REPLACEMENT; SPECIFICITY; REVEALS;
D O I
10.1074/jbc.M112.358523
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heparan sulfate (HS) and heparin are highly sulfated polysaccharides. Heparin is a commonly used anticoagulant drug that inhibits the activities of factors Xa and IIa (also known as thrombin) to prevent blood clot formation. Here, we report the synthesis of a series of size-defined oligosaccharides to probe the minimum size requirement for an oligosaccharide with anti-IIa activity. The synthesis was completed by a chemoenzymatic approach involving glycosyltransferases, HS sulfotransferases, and C-5-epimerase. We demonstrate the ability to synthesize highly purified N-sulfo-oligosaccharides having up to 21 saccharide residues. The results from anti-Xa and anti-IIa activity measurements revealed that an oligosaccharide longer than 19 saccharide residues is necessary to display anti-IIa activity. The oligosaccharides also exhibit low binding toward platelet factor 4, raising the possibility of preparing a synthetic heparin with a reduced effect of heparin-induced thrombocytopenia. The results from this study demonstrate the ability to synthesize large HS oligosaccharides and provide a unique tool to probe the structure and function relationships of HS that require the use of large HS fragments.
引用
收藏
页码:29054 / 29061
页数:8
相关论文
共 50 条
  • [1] Synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities
    Xu, Yongmei
    Stancanelli, Eduardo
    Su, Guowei
    Liu, Jian
    [J]. GLYCOBIOLOGY, 2023, 33 (11) : 1057 - 1057
  • [2] Reproducibility of the anti-Factor Xa and anti-Factor IIa assays applied to enoxaparin solution
    Martinez, Celine
    Savadogo, Adama
    Agut, Christophe
    Anger, Pascal
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 81-82 : 138 - 145
  • [3] Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation
    Gerotziafas, G. T.
    Petropoulou, A. D.
    Verdy, E.
    Samama, M. M.
    Elalamy, I.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (05) : 955 - 962
  • [4] Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors
    Stuart, Morgan
    Johnson, Linda
    Hanigan, Sarah
    Pipe, Steven W.
    Li, Shih-Hon
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1653 - 1660
  • [5] Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol
    Williams-Norwood, Tanya
    Caswell, Megan
    Milner, Barbara
    Vescera, Joseph C.
    Prymicz, Kelly
    Ciszak, Amy G.
    Ingle, Carol
    Lacey, Christopher
    Stavrou, Evi X.
    [J]. AACN ADVANCED CRITICAL CARE, 2020, 31 (02) : 129 - 137
  • [6] IS ANTI-FACTOR XA ACTIVITY IMPORTANT
    HEMKER, HC
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1990, 116 (02): : 268 - 268
  • [7] Potency evaluation of unfractionated heparins commercialized in Brazil through anti-factor Xa and anti-factor IIa chromogenic tests and coagulation assay
    Medeiros, Renata Jurema
    Goncalves, Nathalia Pessoa
    Magalhaes, Magno Maciel
    Martins, Joao Ferreira
    Machado, Tiago Savignon Cardoso
    [J]. VIGILANCIA SANITARIA EM DEBATE-SOCIEDADE CIENCIA & TECNOLOGIA, 2023, 11
  • [8] Potency evaluation of unfractionated heparins commercialized in Brazil through anti-factor Xa and anti-factor IIa chromogenic tests and coagulation assay
    Medeiros, Renata Jurema
    Goncalves, Nathalia Pessoa
    Magalhaes, Magno Maciel
    Martins, Joao Ferreira
    Machado, Tiago Savignon Cardoso
    [J]. VIGILANCIA SANITARIA EM DEBATE-SOCIEDADE CIENCIA & TECNOLOGIA, 2023, 11
  • [9] The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
    Wei, Matthew Y.
    Ward, Salena M.
    [J]. HEMATOLOGY REPORTS, 2015, 7 (04) : 80 - 83
  • [10] Anti-factor Xa activities of zingerone with anti-platelet aggregation activity
    Lee, Wonhwa
    Ku, Sae-Kwang
    Kim, Mi-Ae
    Bae, Jong-Sup
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2017, 105 : 186 - 193